| | | | | |
|---|
| Exhibit Number | | | Description | | |
| 3.1 | | | Our Amended and Restated Articles of Incorporation, effective May 6, 2025 (incorporated by reference to Exhibit 5.7 to the Company's Form 8-K, filed May 8, 2025). | | |
| 3.2 | | | Our Amended and Restated Bylaws, effective October 23, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Form 10-Q report for the quarter ended September 30, 2023, filed October 26, 2023). | | |
| 4.1 | | | Articles 5, 8(c) and 9 of our Amended and Restated Articles of Incorporation, effective May 6, 2025 (incorporated by reference to Exhibit 5.7 to the Company's Form 8-K, filed May 8, 2025). | | |
| 4.2 | | | Articles I and IV of our Bylaws, as amended through October 23, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Form 10-Q report for the quarter ended September 30, 2023, filed October 26, 2023). | | |
| 4.3 | | | Description of Registered Securities (incorporated by reference to Exhibit 4.3 to the Company's Form 10-K report for the year ended December 31, 2025, filed February 17, 2026) | | |
| 4.4(1) | | | Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted. | | |
| 10.1(2)(3) | | | Amended and Restated Technology Exchange and CrossLicense Agreement, dated and effective July 14, 2026, between Daikyo Seiko, Ltd. and us. | | |
| 10.2(2)(3) | | | Distributorship Agreement, dated and effective July 14, 2026, between Daikyo Seiko, Ltd. and us. | | |
| 10.3(2)(3) | | | Distributorship Agreement, dated and effective July 14, 2026, between us and Daikyo Seiko, Ltd. | | |
| 31.1 | | | Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | |
| 31.2 | | | Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | |
| 32.1* | | | Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | |
| 32.2* | | | Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | |
| 101.INS | | | The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. | | |
| 101.SCH | | | Inline XBRL Taxonomy Extension Schema Document | | |
| 101.CAL | | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | |
| 101.LAB | | | Inline XBRL Taxonomy Extension Label Linkbase Document | | |
| 101.PRE | | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | |
| 101.DEF | | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | |
| 104 | | | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. | | |
(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.
(2) Certain information has been excluded from this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.
(3) Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.
Certain portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment order of the SEC.
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)
By: /s/ Robert W. McMahon
Robert W. McMahon
Senior Vice President, Chief Financial Officer
October 29, 2026